Untangling a cancer signaling network suggests new roadmap to tumor control

In this advanced age of molecular sleuthing, a research team led by Georgetown Lombardi Comprehensive Cancer Center have findings that suggest tumors will eventually become resistant to drug inhibitors of a common cancer pathway (dubbed YAP/TAZ), now in preclinical development. But in the same study, published in Developmental Cell, they posit that pairing those inhibitors with another drug, now on the market, may deliver that desired fatal blow.
Source: EurekaAlert, https://www.eurekalert.org